tradingkey.logo

Adagio Medical Holdings Inc

ADGM
View Detailed Chart
1.040USD
0.000
Market hours ETQuotes delayed by 15 min
16.00MMarket Cap
LossP/E TTM

Adagio Medical Holdings Inc

1.040
0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-18.11%

1 Month

-48.00%

6 Months

-17.46%

Year to Date

-0.95%

1 Year

-61.62%

View Detailed Chart

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high.

Adagio Medical Holdings Inc's Score

Industry at a Glance

Industry Ranking
165 / 210
Overall Ranking
534 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Adagio Medical Holdings Inc Highlights

StrengthsRisks
Adagio Medical Holdings, Inc. is a medical device company developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. A standalone PFA console connected to a cryoablation console for PFCA treatment synchronization is used in conjunction with Cryopulse catheter. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for treatment of the ventricular arrhythmia. Its product offerings consist largely of the single use ablation catheters and consoles.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 218.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 602.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 602.00K.
Overvalued
The company’s latest PE is -0.22, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.12M shares, decreasing 24.43% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 21.67K shares of this stock.

Adagio Medical Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Adagio Medical Holdings Inc Info

Adagio Medical Holdings, Inc. is a medical device company developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. A standalone PFA console connected to a cryoablation console for PFCA treatment synchronization is used in conjunction with Cryopulse catheter. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for treatment of the ventricular arrhythmia. Its product offerings consist largely of the single use ablation catheters and consoles.
Ticker SymbolADGM
CompanyAdagio Medical Holdings Inc
CEOMr. Todd Usen
Website
KeyAI